Publication | Closed Access

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial

InflammationBiosimilar Ct-p13Originator InfliximabGastroenterologyClinical TrialsPathologyInflammatory MarkerNon-inferiority TrialUlcerative ColitisMedicine